Peter Damman1, Tibor Kempf2, Fons Windhausen1, Jan P van Straalen3, Anja Guba-Quint2, Johan Fischer3, Jan G P Tijssen1, Kai C Wollert2, Robbert J de Winter4, Alexander Hirsch1. 1. Department of Cardiology, Academic Medical Center - University of Amsterdam, Amsterdam, The Netherlands. 2. Division of Molecular and Translational Cardiology, Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany. 3. Department of Clinical Chemistry, Academic Medical Center - University of Amsterdam, Amsterdam, The Netherlands. 4. Department of Cardiology, Academic Medical Center - University of Amsterdam, Amsterdam, The Netherlands. Electronic address: r.j.dewinter@amc.uva.nl.
Abstract
BACKGROUND: No five-year long-term follow-up data is available regarding the prognostic value of GDF-15. Our aim is to evaluate the long-term prognostic value of admission growth-differentiation factor 15 (GDF-15) regarding death or myocardial infarction (MI) in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). METHODS: This is a subanalysis from the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial, including troponin positive NSTE-ACS patients. The main outcome for the current analysis was 5-year death or spontaneous MI. GDF-15 samples were available in 1151 patients. The prognostic value of GDF-15, categorized into <1200 ng/L, 1200-1800 ng/L and >1800 ng/L, was assessed in unadjusted and adjusted Cox regression models. Adjustments were made for identified univariable risk factors. The additional discriminative and reclassification value of GDF-15 beyond the independent risk factors was assessed by the category-free net reclassification improvement (1/2 NRI(>0)) and the integrated discrimination improvement (IDI) RESULTS: Compared to GDF-15<1200 ng/L, a GDF-15>1800 ng/L was associated with an increased hazard ratio for death or spontaneous MI, mainly driven by mortality. GDF-15 levels were predictive after adjustments for other identified predictors. Additional discriminative value was shown with the IDI, not with the NRI. CONCLUSION: In patients presenting with NSTE-ACS and elevated troponin T, GDF-15 provides prognostic information in addition to identified predictors for mortality and spontaneous MI and can be used to identify patients at high risk during long-term follow-up.
RCT Entities:
BACKGROUND: No five-year long-term follow-up data is available regarding the prognostic value of GDF-15. Our aim is to evaluate the long-term prognostic value of admission growth-differentiation factor 15 (GDF-15) regarding death or myocardial infarction (MI) in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). METHODS: This is a subanalysis from the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial, including troponin positive NSTE-ACSpatients. The main outcome for the current analysis was 5-year death or spontaneous MI. GDF-15 samples were available in 1151 patients. The prognostic value of GDF-15, categorized into <1200 ng/L, 1200-1800 ng/L and >1800 ng/L, was assessed in unadjusted and adjusted Cox regression models. Adjustments were made for identified univariable risk factors. The additional discriminative and reclassification value of GDF-15 beyond the independent risk factors was assessed by the category-free net reclassification improvement (1/2 NRI(>0)) and the integrated discrimination improvement (IDI) RESULTS: Compared to GDF-15<1200 ng/L, a GDF-15>1800 ng/L was associated with an increased hazard ratio for death or spontaneous MI, mainly driven by mortality. GDF-15 levels were predictive after adjustments for other identified predictors. Additional discriminative value was shown with the IDI, not with the NRI. CONCLUSION: In patients presenting with NSTE-ACS and elevated troponin T, GDF-15 provides prognostic information in addition to identified predictors for mortality and spontaneous MI and can be used to identify patients at high risk during long-term follow-up.
Authors: Serdar Farhan; Matthias K Freynhofer; Ivan Brozovic; Veronika Bruno; Birgit Vogel; Ioannis Tentzeris; Sabina Baumgartner-Parzer; Kurt Huber; Alexandra Kautzky-Willer Journal: Cardiovasc Diabetol Date: 2016-04-08 Impact factor: 9.951
Authors: Aleksandra Gombozhapova; Yuliya Rogovskaya; Vladimir Shurupov; Mariya Rebenkova; Julia Kzhyshkowska; Sergey V Popov; Rostislav S Karpov; Vyacheslav Ryabov Journal: J Biomed Sci Date: 2017-02-07 Impact factor: 8.410
Authors: Alberto Dominguez-Rodriguez; Pedro Abreu-Gonzalez; Idaira F Hernandez-Baldomero; Pablo Avanzas; Francisco Bosa-Ojeda Journal: Mediators Inflamm Date: 2014-04-15 Impact factor: 4.711